Search Results 571-580 of 18579 for alopecia

1. Phase 2 Study Of Inhaled Lipid Cisplatin In Pulmonary Recurrent Osteosarcoma - Mayo Clinic

   Patients must have recovered sufficiently from all acute adverse effects of prior therapies, excluding alopecia. Patients must have an ECOG performance ...

2. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

3. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Seborrheic dermatitis, Melasma, Vitiligo. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann ...

4. A Study Of Abemaciclib (LY2835219) In Women With HR+, HER2+ Locally Advanced Or Metastatic Breast Cancer - Mayo Clinic

   ... alopecia or peripheral neuropathy. Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and endocrine ...

5. Phase III Study Of Rilvegostomig In Combination With Bevacizumab With Or Without Tremelimumab As First-line Treatment Of Hepatocellular Carcinoma - Mayo Clinic

   * Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline. * Clinically meaningful ...

6. First in Human Study of TORL-4-500 in Participants With Advanced Cancer - Mayo Clinic

   ... alopecia or laboratory abnormalities otherwise meeting eligibility requirements * Received prior chemotherapeutic, investigational, or other therapies for ...

7. Phase 1 Study To Evaluate MEDI4736 In Subjects With Myelodysplastic Syndrome - Mayo Clinic

   Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement;; Subjects with psoriasis ...

8. A Study Of ABBV-085, An Antibody Drug Conjugate, For Patients With Advanced Solid Cancer Tumors - Mayo Clinic

   Unresolved adverse events ≥ Grade 2 from prior anticancer therapy, except for alopecia; Has ongoing hemolysis; Major surgery within ≤ 28 days prior to the ...

9. Study To Investigate The Safety And Effectiveness Of Two Doses Of The Antibody Drug GSK2857916 In Relapsed/Refractory Multiple Myeloma Patients - Mayo Clinic

   ... alopecia and Grade 2 peripheral neuropathy. For France only: A subject will be eligible for inclusion in this study only if either affiliated to or a ...

10. Melanoma - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Vascular anomaly, Nonmelanoma skin cancer, Tuberous ...